Penumbra, Inc. (NYSE:PEN) Director Sells $96,094.80 in Stock

Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 360 shares of the firm’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $266.93, for a total value of $96,094.80. Following the sale, the director now directly owns 4,692 shares in the company, valued at approximately $1,252,435.56. This trade represents a 7.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Thomas Wilder also recently made the following trade(s):

• On Monday, March 31st, Thomas Wilder sold 360 shares of Penumbra stock. The shares were sold at an average price of $264.58, for a total value of $95,248.80.

Penumbra Price Performance

Shares of NYSE PEN opened at $262.37 on Friday. The firm has a market capitalization of $10.11 billion, a P/E ratio of 771.66, a P/E/G ratio of 2.83 and a beta of 0.51. The firm’s 50-day moving average price is $274.48 and its 200-day moving average price is $245.61. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 1-year low of $148.00 and a 1-year high of $310.00.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The business had revenue of $315.52 million for the quarter, compared to the consensus estimate of $311.63 million. Equities research analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Institutional Trading of Penumbra

Several hedge funds have recently bought and sold shares of PEN. Cerity Partners LLC lifted its stake in shares of Penumbra by 19.2% in the third quarter. Cerity Partners LLC now owns 3,612 shares of the company’s stock valued at $702,000 after buying an additional 583 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Penumbra by 15.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,225 shares of the company’s stock valued at $1,404,000 after acquiring an additional 953 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Penumbra by 1.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 97,571 shares of the company’s stock valued at $18,959,000 after purchasing an additional 995 shares during the last quarter. Edgestream Partners L.P. bought a new stake in Penumbra during the 3rd quarter worth approximately $773,000. Finally, Paloma Partners Management Co purchased a new stake in shares of Penumbra in the third quarter worth approximately $253,000. Institutional investors and hedge funds own 88.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Wells Fargo & Company raised their price objective on shares of Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. JPMorgan Chase & Co. lifted their price target on shares of Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Oppenheimer began coverage on Penumbra in a report on Tuesday, December 17th. They issued an “outperform” rating and a $275.00 price objective for the company. Morgan Stanley lifted their target price on Penumbra from $240.00 to $260.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 19th. Finally, UBS Group increased their price target on Penumbra from $305.00 to $320.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $294.47.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.